BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 28025866)

  • 21. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
    Barosi G
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between JAK2V617F mutation, allele burden and coagulation function in Ph-negative myeloproliferative neoplasms.
    Hu L; Pu L; Ding Y; Li M; Cabanero M; Xie J; Zhou D; Yang D; Zhang C; Wang H; Zhai Z; Ru X; Li J; Xiong S
    Hematology; 2017 Jul; 22(6):354-360. PubMed ID: 27976991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders.
    Passamonti F; Vanelli L; Malabarba L; Rumi E; Pungolino E; Malcovati L; Pascutto C; Morra E; Lazzarino M; Cazzola M
    Haematologica; 2003 Oct; 88(10):1123-9. PubMed ID: 14555308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Flow cytometry immunophenotypic analysis of Philadelphia-negative myeloproliferative neoplasms: Correlation with histopathologic features.
    Ouyang J; Zheng W; Shen Q; Goswami M; Jorgensen JL; Medeiros LJ; Wang SA
    Cytometry B Clin Cytom; 2014 Dec; ():. PubMed ID: 25504846
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of CXCL12 processing on CD34+ cell migration in myeloproliferative neoplasms.
    Cho SY; Xu M; Roboz J; Lu M; Mascarenhas J; Hoffman R
    Cancer Res; 2010 Apr; 70(8):3402-10. PubMed ID: 20388788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Progenitor cell trafficking in physiologic conditions and in myeloproliferative diseases: quantification of CD34+ cells by polymerase chain reaction.
    Oppliger Leibundgut E; Brunold C; Marti D; Horn MP; Seiler C; Schroeder V; Schmid JP; Tobler A; Zwicky C
    Haematologica; 2005 Jul; 90(7):875-80. PubMed ID: 15996924
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Myelofibrotic and leukemic transformation in 2016 WHO-defined Philadelphia-negative myeloproliferative neoplasm.
    Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Kim SY; Jo DY
    Blood Res; 2022 Mar; 57(1):59-68. PubMed ID: 35256550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: clinical correlates and prognostic studies.
    Pardanani A; Drake MT; Finke C; Lasho TL; Rozell SA; Jimma T; Tefferi A
    Am J Hematol; 2011 Dec; 86(12):1013-6. PubMed ID: 22086864
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of the bioactive and total transforming growth factor β1 levels in primary myelofibrosis.
    Campanelli R; Rosti V; Villani L; Castagno M; Moretti E; Bonetti E; Bergamaschi G; Balduini A; Barosi G; Massa M
    Cytokine; 2011 Jan; 53(1):100-6. PubMed ID: 20801055
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The morphology features of bone marrow in the prefibrotic-early primary myelofibrosis].
    Gong XB; Zhang XH; Lu XG; Tang QS; Gao X; Yang J
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):25-30. PubMed ID: 22575188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm.
    Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Kim SY; Jo DY
    Korean J Intern Med; 2021 Sep; 36(5):1190-1203. PubMed ID: 34289585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
    Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
    Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [JAK2V617F mutation and p-STAT5 protein expression in peripheral blood cells of patients with myeloproliferative neoplasm and their relations with clinical features].
    Chen YX; Li Y; Zhang LY; Liu X; Shan NN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1398-404. PubMed ID: 23257441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The JAK2V617F allele burden and STAT3- and STAT5 phosphorylation in myeloproliferative neoplasms: early prefibrotic myelofibrosis compared with essential thrombocythemia, polycythemia vera and myelofibrosis.
    Risum M; Madelung A; Bondo H; Bzorek M; Kristensen MH; Stamp IM; Hasselbalch HC
    APMIS; 2011 Aug; 119(8):498-504. PubMed ID: 21749449
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms.
    Čokić VP; Mitrović-Ajtić O; Beleslin-Čokić BB; Marković D; Buač M; Diklić M; Kraguljac-Kurtović N; Damjanović S; Milenković P; Gotić M; Raj PK
    Mediators Inflamm; 2015; 2015():453020. PubMed ID: 26491227
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Study of bone marrow microvessel density is one of the diagnostic approaches in patients with Ph-negative chronic myeloproliferative diseases].
    Sokolova MA; Khoroshko ND; Tsvetaeva NV; Semenova EA; Kaplanskaia IB; Frank GA; Misiurin AV
    Ter Arkh; 2010; 82(12):47-51. PubMed ID: 21516739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Coexistence of myeloproliferative neoplasm and plasma-cell dyscrasia.
    Malhotra J; Kremyanskaya M; Schorr E; Hoffman R; Mascarenhas J
    Clin Lymphoma Myeloma Leuk; 2014 Feb; 14(1):31-6. PubMed ID: 24220620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper.
    Barosi G; Vannucchi AM; De Stefano V; Pane F; Passamonti F; Rambaldi A; Saglio G; Barbui T; Tura S
    Leuk Res; 2014 Feb; 38(2):155-60. PubMed ID: 24378116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Our experience with detection of JAK2 mutations in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative disorders].
    Burjanivová T; Marcinek J; Minárik G; Lasabová Z; Szépe P; Balhárek T; Vanochová A; Plank L
    Cesk Patol; 2011 Jul; 47(3):115-7. PubMed ID: 21887928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.